What is the recommended TKI dosage for advanced-stage accelerated-phase chronic myelogenous leukemia (AP-CML) or blast-phase chronic myelogenous leukemia (BP-CML)?

Updated: Oct 23, 2019
  • Author: Rossa Khalaf, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

TKI doses recommended for AP-CML and BP-CML are as follows:

  • Imatinib – 300 mg twice a day or 600 mg once daily
  • Nilotinib – 400 mg twice a day
  • Dasatinib – 140 mg daily
  • Ponatinib – 45 mg once daily
  • Omacetaxine dosing for AP-CML is the same as for CP-CML; omacetaxine is not used in BP-CML

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!